Replies to post #166871 on Cytodyn Inc (CYDY)

[misiu143]

Efficacy SafetyLeronlimab mortality better than placebo No safety issues in CD12 or CD10 clinical trialsCD12: Critically ill population (7-day) 78 % CD12: LL arm 21% less AE/patients (AE/all patients)CD12: Critically ill population (14-day) 82 % CD12: LL arm 3% less SAE/patients (SAE/all patients)CD12: Critically ill population (21-day) 50 % CD10: LL arm 59% less AE/patients (AE/all patients)CD12: Critically ill population (28-day) 31 % CD10: LL arm 64% less SAE/patients (SAE/all patients)Patients in the CD12 trial

And it shows in the last PR with Top Line results how much less of side effects in LL arm compare to just SOC.
Which mean to me that Leronlimab even preventing developing of side effects..

As they saying " Know what you own "

All IMO.

[Leronlimab4DaWin]

Magic Mikey was/is prob wearing a wire. Night night Nader